Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: A case control study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 4, 2012, Pages 797-804

  Tomoda, Takeshi ^a   Nouso, Kazuhiro ^a   Sakai, Akiko ^a   Ouchida, Mamoru ^a   Kobayashi, Sayo ^a   Miyahara, Koji ^a   Onishi, Hideki ^a   Nakamura, Shinichiro ^a   Yamamoto, Kazuhide ^a   Shimizu, Kenji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Hepatocellular carcinoma; Single nucleotide polymorphism

Indexed keywords

CYTOCHROME P450 2C19; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE B; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 10; INTERLEUKIN 1BETA; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 13; PROTEIN MDM2; PROTEIN P53; RAD18 PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84863394227     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06948.x     Document Type: Article

References (46)

1. Liang TJ, Rehermann B, Seeff LB etal. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 2000; 132: 296-305.
2. Shiratori Y, Imazeki F, Moriyama M etal. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 2000; 132: 517-24.
3. Yoshida H, Arakawa Y, Sata M etal. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123: 483-91.
4. Yeh SH, Chen PJ, Shau WY etal. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma. Gastroenterology 2001; 121: 699-709.
5. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999; 30: 595-601.
6. Shastry BS. SNP alleles in human disease and evolution. J. Hum. Genet. 2002; 47: 561-6.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
8. Homann N, Stickel F, Konig IR etal. Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Int. J. Cancer 2006; 118: 1998-2002.
9. Akkiz H, Bayram S, Bekar A etal. Relationship between functional polymorphism in the Aurora A gene and susceptibility of hepatocellular carcinoma. J. Viral Hepat. 2010; 17: 668-74.
10. Akkiz H, Bayram S, Bekar A etal. Cyclin D1 G870A polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case-control study. Cancer Epidemiol. 2010; 34: 298-302.
11. Xiong XD, Fang JH, Qiu FE etal. A novel functional polymorphism in the Cdc6 promoter is associated with the risk for hepatocellular carcinoma. Mutat. Res. 2008; 643: 70-4.
12. Wang XQ, Luk JM, Garcia-Barcelo M etal. Liver intestine-cadherin (CDH17) haplotype is associated with increased risk of hepatocellular carcinoma. Clin. Cancer Res. 2006; 12: 5248-52.
13. Kato N, Ji G, Wang Y etal. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology 2005; 42: 846-53.
14. Hu L, Liu J, Chen X etal. CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infection-related cancers-hepatocellular carcinoma and cervical cancer. Hum. Immunol. 2010; 71: 888-91.
15. Dong X, Zhou G, Zhai Y etal. Association of DLC1 gene polymorphism with susceptibility to hepatocellular carcinoma in Chinese hepatitis B virus carriers. Cancer Epidemiol. 2009; 33: 265-70.
16. Tanabe KK, Lemoine A, Finkelstein DM etal. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008; 299: 53-60.
17. Zhai Y, Zhou G, Deng G etal. Estrogen receptor alpha polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. Gastroenterology 2006; 130: 2001-9.
18. Chen YL, Tseng HS, Kuo WH etal. Glutathione S-Transferase P1 (GSTP1) gene polymorphism increases age-related susceptibility to hepatocellular carcinoma. BMC Med. Genet. 2010; 11: 46-53.
19. Couvert P, Carrie A, Paries J etal. Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma. World J. Gastroenterol. 2008; 14: 5419-27.
20. Wang Y, Kato N, Hoshida Y etal. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 2003; 37: 65-71.
21. Tseng LH, Lin MT, Shau WY etal. Correlation of interleukin-10 gene haplotype with hepatocellular carcinoma in Taiwan. Tissue Antigens 2006; 67: 127-33.
22. Xu Y, Liu L, Liu J etal. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int. J. Cancer 2011; 128: 412-17.
23. Xu T, Zhu Y, Wei QK etal. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 2008; 29: 2126-31.
24. Mu LN, Cao W, Zhang ZF etal. Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and the risk of primary hepatocellular carcinoma (HCC) in a Chinese population. Cancer Causes Control 2007; 18: 665-75.
25. Kwak SY, Kim UK, Cho HJ etal. Methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) gene polymorphisms as risk factors for hepatocellular carcinoma in a Korean population. Anticancer Res. 2008; 28: 2807-11.
26. Segat L, Milanese M, Pirulli D etal. Secreted protein acidic and rich in cysteine (SPARC) gene polymorphism association with hepatocellular carcinoma in Italian patients. J. Gastroenterol. Hepatol. 2009; 24: 1840-6.
27. Kim YJ, Lee HS, Im JP etal. Association of transforming growth factor-beta1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Exp. Mol. Med. 2003; 35: 196-202.
28. Borentain P, Gerolami V, Ananian P etal. DNA-repair and carcinogen-metabolising enzymes genetic polymorphisms as an independent risk factor for hepatocellular carcinoma in Caucasian liver-transplanted patients. Eur. J. Cancer 2007; 43: 2479-86.
29. Dharel N, Kato N, Muroyama R etal. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin. Cancer Res. 2006; 12: 4867-71.
30. Munaka M, Kohshi K, Kawamoto T etal. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2003; 129: 355-60.
31. Yoshida H, Shiratori Y, Moriyama M etal. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann. Intern. Med. 1999; 131: 174-81.
32. Kato S, Tajiri T, Matsukura N etal. Genetic polymorphisms of aldehyde dehydrogenase 2, cytochrome p450 2E1 for liver cancer risk in HCV antibody-positive Japanese patients and the variations of CYP2E1 mRNA expression levels in the liver due to its polymorphism. Scand. J. Gastroenterol. 2003; 38: 886-93.
33. Sakamoto T, Hara M, Higaki Y etal. Influence of alcohol consumption and gene polymorphisms of ADH2 and ALDH2 on hepatocellular carcinoma in a Japanese population. Int. J. Cancer 2006; 118: 1501-7.
34. Nishi R, Okuda Y, Watanabe E etal. Centrin 2 stimulates nucleotide excision repair by interacting with xeroderma pigmentosum group C protein. Mol. Cell. Biol. 2005; 25: 5664-74.
35. Graser S, Stierhof YD, Lavoie SB etal. Cep164, a novel centriole appendage protein required for primary cilium formation. J. Cell Biol. 2007; 179: 321-30.
36. Takano Y, Kato Y, Masuda M etal. Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J. Pathol. 1999; 189: 194-200.
37. Iizuka N, Oka M, Yamada-Okabe H etal. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003; 361: 923-9.
38. Ji C, Shinohara M, Kuhlenkamp J etal. Mechanisms of protection by the betaine-homocysteine methyltransferase/betaine system in HepG2 cells and primary mouse hepatocytes. Hepatology 2007; 46: 1586-96.
39. Chiou JF, Tai CJ, Huang MT etal. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. Ann. Surg. Oncol. 2010; 17: 603-12.
40. Wang Q, He Z, Zhang J etal. Overexpression of endoplasmic reticulum molecular chaperone GRP94 and GRP78 in human lung cancer tissues and its significance. Cancer Detect. Prev. 2005; 29: 544-51.
41. Bond GL, Hu W, Bond EE etal. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
42. Harada S, Agarwal DP, Goedde HW etal. Possible protective role against alcoholism for aldehyde dehydrogenase isozyme deficiency in Japan. Lancet 1982; 2: 827.
43. Cui R, Kamatani Y, Takahashi A etal. Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. Gastroenterology 2009; 137: 1768-75.
44. Ripatti S, Tikkanen E, Orho-Melander M etal. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet 2010; 376: 1393-400.
45. Zheng SL, Sun J, Wiklund F etal. Cumulative association of five genetic variants with prostate cancer. N. Engl. J. Med. 2008; 358: 910-19.
46. Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J. Gastroenterol. 2006; 12: 828-9.